Enrico Cortesi
Overview
Explore the profile of Enrico Cortesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
6396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cucciniello L, Blondeaux E, Bighin C, Gasparro S, Russo S, Dri A, et al.
NPJ Breast Cancer
. 2024 Dec;
10(1):105.
PMID: 39695115
This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the...
2.
Berardi G, Giannelli V, Colasanti M, Cianni R, Meniconi R, Guglielmo N, et al.
Ann Hepatobiliary Pancreat Surg
. 2024 Aug;
28(4):516-521.
PMID: 39099099
Patients with nonresectable breast cancer liver metastasis (BCLM) face a dismal prognosis. Despite liver transplantation (LT) for metastatic liver tumors having recently shown good results, BCLM represents an absolute contraindication....
3.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):68.
PMID: 39095493
No abstract available.
4.
Tenuta M, Mazzotta P, Sesti F, Angelini F, Gelibter A, Speranza I, et al.
Andrology
. 2024 Jul;
13(3):587-599.
PMID: 39078248
Background: Bilateral testicular germ cell tumours (B-GCT) are rare, with an incidence of 2-5%, and can be classified as synchronous (sB-GCT) or metachronous (mB-GCT). Our study aimed to identify clinical,...
5.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):58.
PMID: 39019916
Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2- advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to...
6.
Campagna R, Dominelli F, Zingaropoli M, Ciurluini F, Grilli G, Amoroso A, et al.
Vaccine
. 2024 Mar;
42(10):2687-2694.
PMID: 38499458
Cancer patients (CPs), being immunosuppressed due to the treatment received or to the disease itself, are more susceptible to infections and their potential complications, showing therefore an increased risk of...
7.
Marinelli D, Gallina F, Pannunzio S, Di Civita M, Torchia A, Giusti R, et al.
Crit Rev Oncol Hematol
. 2023 Oct;
192:104190.
PMID: 37871779
The use of neoadjuvant or perioperative anti-PD(L)1 was recently tested in multiple clinical trials. We performed a systematic review and meta-analysis of randomised trials comparing neoadjuvant or perioperative chemoimmunotherapy to...
8.
Tenuta M, Pandozzi C, Sciarra F, Campolo F, Gelibter A, Sirgiovanni G, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509255
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of tumors. Natural killer (NK) cells can play an important role in cancer immune surveillance. The aim of this prospective observational...
9.
Siringo M, Gentile G, Caponnetto S, Sperduti I, Santini D, Cortesi E, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444532
No evidence exists as to whether body mass index (BMI) impairs clinical outcomes from ALK inhibitors (ALKi) in patients with ALK-rearranged non-small cell lung cancer (NSCLC). Retrospective data of patients...
10.
Di Lisa F, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, et al.
Front Oncol
. 2023 Jun;
13:1152123.
PMID: 37260975
Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine,...